MODERNA INC (1MRNA.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1MRNA - US60770K1079 - Common Stock
1MRNA.MI Key Statistics, Chart & Performance
The current stock price of 1MRNA.MI is 27.11 EUR. In the past month the price increased by 14.92%. In the past year, price decreased by -44.51%.
1MRNA.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 69.35 | 45.30B | ||
| 1AE.DE | ARGENX SE | 69.24 | 45.23B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.03B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.78B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.85B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.82B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.82B | ||
| 1CVAC.MI | CUREVAC NV | 5.04 | 987.60M | ||
| NANO.PA | NANOBIOTIX | N/A | 905.49M | ||
| 5CV.DE | CUREVAC NV | 6.03 | 787.64M | ||
| IVA.PA | INVENTIVA SA | N/A | 697.22M | ||
| PHIL.MI | PHILOGEN SPA | 20.44 | 681.29M |
Related stock screener links
About 1MRNA.MI
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS US
Employees: 5800
Phone: 16177146500
MODERNA INC / 1MRNA.MI FAQ
Can you describe the business of MODERNA INC?
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
What is the stock price of MODERNA INC today?
The current stock price of 1MRNA.MI is 27.11 EUR. The price increased by 1.25% in the last trading session.
What is the dividend status of MODERNA INC?
1MRNA.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1MRNA stock?
1MRNA.MI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for 1MRNA.MI stock?
29 analysts have analysed 1MRNA.MI and the average price target is 32.86 EUR. This implies a price increase of 21.22% is expected in the next year compared to the current price of 27.11.
What is the next earnings date for 1MRNA stock?
MODERNA INC (1MRNA.MI) will report earnings on 2026-02-12, after the market close.
1MRNA.MI Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to 1MRNA.MI. When comparing the yearly performance of all stocks, 1MRNA.MI is a bad performer in the overall market: 81.81% of all stocks are doing better.
1MRNA.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI. The financial health of 1MRNA.MI is average, but there are quite some concerns on its profitability.
1MRNA.MI Financial Highlights
Over the last trailing twelve months 1MRNA.MI reported a non-GAAP Earnings per Share(EPS) of -6.89. The EPS decreased by -38.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.68% | ||
| ROE | -33.4% | ||
| Debt/Equity | 0 |
1MRNA.MI Forecast & Estimates
29 analysts have analysed 1MRNA.MI and the average price target is 32.86 EUR. This implies a price increase of 21.22% is expected in the next year compared to the current price of 27.11.
For the next year, analysts expect an EPS growth of 10.49% and a revenue growth -41.03% for 1MRNA.MI